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http://dx.doi.org/10.1016/j.jfma.201
0929-6646/Copyright ª 2015, FormosaBackground/Purpose: Immunosuppressive therapy plays an important role in patients with
high-risk idiopathic membranous nephropathy (IMN), but the therapeutic modality is still
controversial.
Methods: Corticosteroid combined with oral tacrolimus (TAC, target trough blood concentra-
tion of 4e8 ng/mL), intravenous cyclophosphamide (CYC, 750 mg/m2/mo, or oral mycopheno-
late mofetil (MMF, 1.5e2.0 g/d) were randomly administered for 9 months to 90 patients with
IMN proved with renal biopsy with severe proteinuria (>8 g/d).
Results: Eighty-six of the 90 patients completed the study. The total remission (TR) rates in the
TAC group were significantly higher than those in the CYC group at 1 and 2 months (p < 0.01)
and the MMF group at 1e4 months (p < 0.01). The TR rates were 83.3%, 73.3%, and 70.0% in the
TAC, CYC, and MMF groups at 9 months (pZ 0.457), and there were no significant differences
between the three groups from 5 to 9 months. Furthermore, TAC reduced proteinuria and
ameliorated hypoalbuminemia more quickly and effectively than CYC and MMF. We observed
no severe adverse events in the three groups.
Conclusion: Tacrolimus combined with corticosteroid had tolerable adverse effects and
induced the remission of IMN more effectively and more rapidly. This is the first prospective
randomized cohort study to compare three different therapies in patients at high risk for
IMN. It provides strong evidence for choosing optimal treatment for patients with IMN. The
long-term efficacy of this treatment strategy should be investigated further in future studies.
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12 L. Peng et al.IntroductionIdiopathic membranous nephropathy (IMN) is one of the
leading causes of primary nephrotic syndrome regardless of
race.1,2 The interaction of circulating autoantibodies with
native antigens and the embedding of these autoantibodies
in the podocyte cell membraneebasement membrane
interface are generally regarded as the fundamental
pathobiological mechanism of the disease. The in situ for-
mation of subepithelial immune deposits alters glomerular
capillary permeability through complement-mediated
injury of the podocyte and its slit pore membrane,3 and
abnormal activation of the immune system is essential for
the occurrence and development of IMN. IMN is also
regarded as a podocytopathy, and podocytes play a central
role in proteinuria and renal function loss during this
process.3
Treatment of IMN is controversial because of different
possible types of IMN disease progression. Generally,
approximately one third of patients achieve spontaneous
remission, but another one third of patients will suffer from
end-stage renal disease (ESRD).4 The patients with consid-
erable proteinuria are prone to ESRD. Immunosuppressive
therapy is important in the treatment of IMN, especially in
high-risk patients.5 The Kidney Disease: Improving Global
Outcomes (KDIGO) initiative recommends that the initial
therapy for IMN should be started only in patients with
nephrotic syndrome whose urinary protein excretion
persistently exceeds 4 g/d, remains at >50% of the baseline
value, and does not show a progressive decline during
antihypertensive and antiproteinuric therapy over an
observation period of at least 6 months (1B) or in patients
with severe, disabling, or life-threatening symptoms related
to their nephrotic syndrome (1C).6 Early treatment is rela-
tively important, and if successful, it can reduce the risk of
complications associated with nephrotic syndrome.7
The immunosuppressive treatment of IMN is still a
matter of debate. Some authors observed that oral
cyclophosphamide (CYC) was effective when used early in
the course of IMN,8e10 whereas other investigators found
that the use of intravenous CYC combined with oral cor-
ticosteroids was safer and more effective.11 Although
mycophenolate mofetil (MMF) monotherapy did not
decrease proteinuria or increase partial and complete
remissions in IMN compared with a control group that un-
derwent basic treatment,12 a regimen of MMF with pred-
nisolone can induce remission in more than 60% of patients
with IMN.13 Tacrolimus (TAC) monotherapy was recently
suggested to be a useful therapeutic option for patients
with IMN.14 Furthermore, several IMN trials are being
performed to compare a TAC-corticosteroid combination
with a CYC-steroid combination.15e18 Other investigations
have shown that the actin cytoskeleton of podocytes is a
direct target of the antiproteinuric effect of the calci-
neurin inhibitor.19 Our recent study also confirmed that
TAC can reduce angiopoietin-like-4 in podocyte to
decrease proteinuria in the early phase in experimental
membranous nephropathy.20 TAC could have the added
benefits of antiproteinuria activity in IMN independent of
its immunological effects. The current prospective ran-
domized cohort study was conducted to compare differentimmunosuppressive therapies to identify agents that offer
a greater remission rate with fewer adverse effects.
Patients and methods
Patients
This prospective randomized cohort study was conducted
from January 2009 to May 2013. Ninety adult patients from
the Second Affiliated Hospital of Harbin Medical University
in China aged 18 to 75 years were recruited for this study.
All participating patients signed the informed consent.
They all received a diagnosis of membranous nephropathy
by renal biopsy and laboratory examination. All of them had
persistent proteinuria (> 8 g/d) after observation for at
least 1 month and met the diagnostic criteria for nephrotic
syndrome. They had not previously received any immuno-
suppressive treatment. The patients who had serum
creatinine levels >133 mmol/L, active infection, diabetes
mellitus, autoimmune disease, tumors, liver function test
abnormalities, or active peptic ulcer disease were
excluded. This study was approved by the ethics committee
of the Second Affiliated Hospital of Harbin Medical Uni-
versity and was conducted according to the principles of
the Declaration of Helsinki.
Study design and immunosuppressive regimens
The 90 patients were randomly administered corticosteroid
combined with TAC, CYC, or MMF. TAC was administered at
0.05 mg/kg/d divided into two doses at intervals of 12 hours
initially. The dose was adjusted to achieve a blood trough
concentration of 4e8 ng/mL for 6 months and then reduced
to 2e4 ng/mL in the subsequent 3 months. CYC was
administered by intravenous injection at a the dose of
750 mg/m2 once a month for 6 months, which was then
reduced to 750 mg/m2 every 3 months. Patients received
MMF at 1.5e2.0 g/d in two doses. Oral corticosteroid was
administered at a dose of 0.5 mg/kg/d in the TAC group and
1 mg/kg/d in the other two groups for 2 months, which was
reduced by 5 mg/d every 2 weeks to 20 mg/d. At that point,
corticosteroid was tapered to zero according to the condi-
tion of the patient. This study lasted for 9 months after the
immunosuppressants were prescribed.
Symptomatic treatment
Antihypertensive agents were administered to achieve a
target blood pressure (systolic < 130 mmHg and diastolic <
80 mmHg). Angiotensin-converting enzyme inhibitors
(ACEIs) or angiotensin receptor blockers were not initiated
during follow up, but were continued in patients who were
already on such treatment prior to recruitment. Anticoag-
ulant drugs and simvastatin were also prescribed to all the
patients.
Outcome parameters
The end point of this study was complete remission (CR) or
partial remission (PR). CR was defined as a daily proteinuria
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and stable renal function. PR was defined as proteinuria of
0.3e3.5 g/d that had declined to 50% of the baseline
value with a serum albumin concentration of at least 30 g/L
and a stable renal function. No response (NR) was defined
as a value for proteinuria 3.5 g/d or a value of 0.3e3.5 g/
d, but with a serum albumin concentration of less than
30 g/L or an increase in the serum creatinine concentration
greater than 50% above the baseline value. Relapse was
defined as a proteinuria >3.5 g/d in two consecutive
measurements in patients with CR or PR, and not recovering
within 2 weeks. Total remission (TR) was defined as either
CR or PR.
Statistical methods
Continuous variables are described as the mean  standard
deviation (SD), and categorical variables are presented as
numbers and percentages. For the comparison of the basic
information in patients between groups, one-way analysis
of variance (ANOVA) was used when the data had a gaussian
distribution, and the Kruskal-Wallis H-test was used when
the data had a nongaussian distribution. The incidence of
remission was compared using the chi-square test with
partitions of the chi-square method and Bonferroni
correction for the post hoc test. The log rank test was used
to compare the time for patients to get to the endpoint
events. For the comparison of the proteinuria, serum al-
bumin, and serum creatinine, repeated-measures ANOVA
with Fisher post hoc test and Bonferroni correction was
used. Statistical analyses were conducted in SPSS (version
21.0; IBM, Chicago, IL, USA). A value of p < 0.05 was
considered statistically significant.
Results
Baseline characteristics of patients
In this study, 30 patients were assigned to the TAC group, 30
to the CYC group, and 30 to the MMF group. There was no
difference between the three groups with respect to clin-
ical or pathological characteristics (Table 1).
Response to treatment
In the TAC group, one patient died because of severe
infection and gastrointestinal bleeding. In the CYC group,
one patient suffered leukopenia and quit this trial and one
patient was lost in the follow-up period. In the MMF group,
one patient died due to infection. The NR rates were 6.67%,
20%, and 20% in the TAC, CYC, and MMF group at 6 months
(p Z 0.258). The NR rates at 9 months still showed no
significant difference between three groups. In the last 3
months of follow-up, two patients in the TAC group, one in
the CYC group, and two in the MMF group suffered relapse
after attaining PR (p Z 0.809; Figure 1).
The remission rates based on the intention-to-treat
analysis are shown in Table 2 and Figure 2. The TR rates
of the TAC group was significantly higher than those of the
CYC group at 1 and 2 months (p < 0.01), and higher thanthose of the MMF group at 1, 2, 3, and 4 months (p < 0.01).
However, the TR rates of the TAC group were not signifi-
cantly different from those of the CYC group from 3 to 9
months, and the MMF group from 5 to 9 months. The PR
rates of the TAC group was higher than those of the CYC and
MMF groups at 1 and 2 months (p < 0.01). The CR rates of
the TAC group were significantly higher than those of the
CYC group from 3 to 6 months and MMF group from 3 to 9
months (p < 0.01). The aforementioned results indicated
that TAC can improve remission in the early stage and can
induce the remission faster in patients with IMN than can
CYC and MMF. Similar to the intention-to-treat analysis, the
per-protocol analysis showed almost the same results and
indicated that TAC can improve remission in patients with
early-stage IMN.
The mean time of attaining remission excluding the NR
patients was 2.6  1.4 months in the TAC group, 3.8  1.3
months in the CYC group, and 4.3  1.3 months in the MMF
group. There were significant differences between the TAC
and CYC groups (pZ 0.006) and between the TAC and MMF
groups (p < 0.001); however, there was no difference be-
tween the CYC and MMF groups (p Z 0.838). In the TAC
group, CR began to emerge at 2 months, whereas CR did not
emerge until 4 months in the CYC and the MMF groups. The
log-rank test revealed significant differences in CR emer-
gence between the TAC and the CYC groups (p Z 0.006),
and between the TAC and the MMF group (p Z 0.002). The
PR emergence showed the similar significant differences
between the TAC and the CYC groups (p Z 0.004), and
between the TAC and the MMF group (p < 0.001) by log rank
test (Figure 3). The aforementioned results indicated that
TAC can induce remissions (both PR and CR) more quickly
than CYC and MMF.Changes in urinary protein, serum albumin, and
serum creatinine
The change of urinary protein is shown in Table 3.
Repeated-measures ANOVA showed that proteinuria in the
TAC group decreased significantly compared with that in
the CYC group (pZ 0.001) and the MMF group (p < 0.001),
but the decrease in proteinuria was not significant between
the CYC and MMF groups (p Z 0.356). The post hoc test
showed that the level of proteinuria in the TAC group was
significantly lower than that in the CYC group at 1e5
months (p < 0.05), whereas there was no significant dif-
ference between the two groups from 6 to 9 months. Pro-
teinuria in the TAC group was also significantly lower than
that in the MMF group from 1 to 6 months (p < 0.05),
whereas there was no significant difference between the
two groups from 7 to 9 months. The aforementioned results
indicated that TAC can reduce proteinuria in patients with
IMN more effectively than CYC and MMF, especially in the
early stage of the disease.
The change of serum albumin is shown in Table 4.
Repeated-measures ANOVA showed that serum albumin in
the TAC group increased significantly compared with that in
the CYC group (pZ 0.002) and the MMF group (pZ 0.019),
but the increase in serum albumin was not significant be-
tween the CYC and MMF groups (p Z 0.444). The post hoc
test showed that the level of serum albumin in the TAC
Table 1 Basic patient information.
TAC group (N Z 30) CYC group (N Z 30) MMF group (N Z 30) p
Age (y) 43.9  13.2 40.8  13.3 39.9  14.3 0.512
Male:female 17:13 16:14 14:16 0.732
Urinary protein (g/d) 11.7  3.2 11.9  1.5 12.1  3.7 0.345
Serum albumin (g/L) 20.5  3.4 19.8  3.8 21.9  4.9 0.260
T-CH (mmol/L) 10.4  3.2 10.1  2.6 9.8  3.1 0.880
TG (mmol/L) 3.3  2.0 2.8  1.2 2.9  1.2 0.952
Scr (mmol/L) 82.4  13.6 78.4  13.8 78.7  13.8 0.449
Ccr (mL/min) 87.9  16.5 97.3  23.0 95.8  24.9 0.258
Hypertension (n) 8 7 5 0.638
Systolic (mmHg) 122.3  16.1 123.3  14.0 122.1  12.6 0.926
Diastolic (mmHg) 78.5  10.5 77.7  8.5 80.2  10.4 0.620
ACEI/ARB used (n) 8 7 5 0.638
Renal biopsy (Ⅰ/Ⅱ/Ⅲ/Ⅳ) (n) 10/15/5/0 10/13/7/0 12/13/5/0 0.922
ACEI Z angiotensin-converting enzyme inhibitor; ARB Z Angiotensin Receptor Blocker; Ccr Z creatinine clearance;
CYC Z cyclophosphamide; MMF Z mycophenolate mofetil; Scr Z serum creatine; TAC Z tacrolimus; T-CH Z total cholesterol;
TG Z triglyceride.
A value of p < 0.05 was defined as statistically significant.
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1 to 6 months (p < 0.05), whereas there was no significant
difference between the two groups from 7 to 9 months.
Serum albumin in the TAC group was also significantly
higher than that in the MMF group from 2 to 6 months
(p < 0.05), whereas there was no significant difference
between the two groups from 7 to 9 months. These resultsFigure 1 Total number of patients, random assignment, and tre
between the TAC, CYC, and MMF groups at 6 and 9 months (p Z
significantly different between the three groups (p Z 0.809
MMFZ mycophenolate mofetil; NRZ the patients did not achieve
PR, partial remission; TAC Z tacrolimus.indicate that TAC can ameliorate hypoalbuminemia in pa-
tients with IMN more effectively than can CYC and MMF.
Serum creatinine during the 9-month treatment period
remained stable. There was no serum creatinine increase >
30% in any patient. In addition, there was no difference
between the three groups at any time points. Blood pres-
sure was also similar between the pretreatment and post-atment results. The NR rates were not significantly different
0.258 and 0.311, respectively). The relapse rates were not
). CR Z complete remission; CYC Z cyclophosphamide;
either complete remission or partial remission within 9 months;
Table 2 Remission rates during 9 months (%).
Mo PR CR TR
TAC CYC MMF TAC CYC MMF TAC CYC MMF
1 20.0 0.0* 0.0* 0.0 0.0 0.0 20.0 0.0*** 0.0***
2 40.0 6.7* 3.3* 13.3 0.0 0.0 53.3 6.7*** 3.3***
3 46.7 40.0 30.0 23.3 0.0** 0.0** 70.0 40.0 30.0***
4 50.0 46.7 30.0 33.3 6.7** 3.3** 83.3 53.3 33.3***
5 43.3 60.0 53.3 40.0 10.0** 10.0** 83.3 70.0 63.3
6 43.3 56.7 63.3 46.7 16.7** 13.3** 90.0 73.3 76.7
9 30.0 46.7 50.0 53.3 26.7 20.0** 83.3 73.3 70.0
*p < 0.01, vs. the PR rates of the TAC group at the same time
point.
**p < 0.01, vs. the CR rates of the TAC group at the same time
point.
***p < 0.01, vs. the TR rates of the TAC group at the same time
point.
CR Z complete remission; CYC Z cyclophosphamide;
MMF Z mycophenolate mofetil; PR Z partial remission,
TAC Z tacrolimus; TR Z total remission.
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any patient.Adverse events
The adverse events during the treatment period are shown
in Table 5. Twenty-one patients contracted infections,
including respiratory and urinary system infections,
namely, six in the TAC group, seven in the CYC group, and
eight in the MMF group. Two patients in the TAC group,
three in the CYC group, and two in the MMF group had a
temporary increase in transaminase, which was restored to
normal by hepatoprotective drugs. Hand tremor was com-
mon in the TAC group. Six patients suffered from hand
tremor in the TAC group and exhibited a slight improvement
after drug dosage reduction. Leukopenia was observed in
the CYC group (white blood cells [WBC] < 2.0  109/L) afterFigure 2 The remission rates in the tacrolimus, cyclophos-
phamide, and cyclophosphamide groups during 9 months.
CR Z complete remission; CYC Z cyclophosphamide;
MMF Z mycophenolate mofetil; PR Z partial remission;
TAC Z tacrolimus.1 month of treatment. There was no obvious increase in
WBC by reducing the drug dose, so we stopped the intra-
venous CYC. Another patient was lost to follow-up at 3
months in the CYC group. In the TAC group, one patient
exhibited progressive diabetes mellitus and subcutaneous
insulin was administered. Gastrointestinal reactions were
found in the CYC and MMF groups. Alopecia was found in
the CYC group. A 75-year-old male patient died from severe
respiratory system infection and gastrointestinal bleeding
after 3 months on TAC combined with prednisolone. A 70-
year-old male patient died from severe respiratory
system infection after 5 months on MMF combined with
prednisolone.Discussion
IMN is one of the most common pathological types of
nephrotic syndrome in adults.21 Considering the toxic ef-
fects of immunosuppressive therapy, some investigators
advocate delaying treatment in case of spontaneous re-
missions,18,21,22 although this will increase the risk of
complications of nephritic syndrome, such as thromboem-
bolism, cardiovascular disease, and infection, in patients
who do not achieve spontaneous remission. It seems
necessary but difficult to accurately determine the prog-
nosis of IMN. Cattran et al23 established a robust model
incorporating clinical observations to predict the renal
outcome of IMN. They defined the individuals with declining
renal function or persistent high-grade proteinuria (>8 g/d,
regardless of the level of renal function) during 6 months of
observation as patients at the highest risk of a poor renal
outcome. Patients in this group are less likely to achieve
spontaneous remission and should receive immunosup-
pressive therapy. Chinese patients with severe proteinuria
and nephrotic syndrome cannot afford to undergo long-
term observation without effective treatment. In our
study, the proteinuria level in all the patients was >8 g/d,
so immunosuppressive therapy was administered without
delay. Early treatment, if successful, can reduce the risk of
complications associated with nephritic syndrome and can
prevent progression to renal failure.24
In this study, in high-risk patients with IMN, early
treatment with TAC, CYC, or MMF with corticosteroid was
effective. Urine protein decreased and serum albumin
increased significantly in all three groups during the 9-
month observation period. Although the monthly dose of
intravenous CYC (750 mg/m2) was lower than that of oral
CYC (1.5e2.0 mg/kg/d) in other trials, our data indicate
that this treatment protocol achieved a high remission rate
(73.3%) in Chinese patients with IMN at 9 months. This rate
was close to that found in two previous trials (72.3% and
85.7%).8,25 The reason why our remission rate was higher
than one of the current two trials may be the early initia-
tion of treatment.8 Compared with another trial in which
early CYC treatment was administered, our remission rate
was lower, possibly because of the lower dose of CYC
administered.25 In our study, the remission rate in the MMF
group (70.0%) was higher than that of two studies that used
similar doses of MMF (63.6% and 63.6%, respectively).13,26
This result may also have been due to the early initiation
of treatment. TAC has demonstrated better efficacy and
Table 4 Serum albumin change during 9 months. change during 9 months (g/d).
Group Serum albumin change over time (g/L)
Mo 1 Mo 2 Mo 3 Mo 4 Mo 5 Mo 6 Mo 7 Mo 8 Mo 9
TAC 28.0  3.0 32.3  3.4 33.8  3.5 36.5  3.4 37.4  3.4 38.7  4.3 37.6  4.3 38.2  4.8 38.7  4.3
CYC 23.4  4.2* 27.0  3.9* 30.2  3.9* 33.1  4.6* 35.0  4.7* 36.3  4.9* 36.9  4.8 36.4  4.7 36.6  5.6
MMF 25.9  4.7 28.0  5.1* 30.7  4.4* 31.5  4.4* 34.1  4.3* 36.4  3.2* 36.2  3.7 36.5  4.0 37.5  4.0
*p < 0.05, vs. TAC group at the same time point.
CYC Z cyclophosphamide; MMF Z mycophenolate mofetil; TAC Z tacrolimus.
Figure 3 Probability of complete remission and partial remission in the tacrolimus, cyclophosphamide, and cyclophosphamide
groups. (A) Probability of complete remission. The log-rank test revealed significant differences in CR emergence between the TAC
and the CYC groups (pZ 0.006), and between the TAC and the MMF group (pZ 0.002). (B) Probability of partial remission. The PR
emergence showed significant differences between the TAC and the CYC groups (p Z 0.004), and between the TAC and the MMF
group (p < 0.001) by log rank test. CR Z complete remission; CYC Z cyclophosphamide; MMF Z mycophenolate mofetil;
PR Z partial remission; TAC Z tacrolimus.
Table 3 Urinary protein change during 9 months.
Group Urinary protein change over time (g/d)
Mo 0 Mo 1 Mo 2 Mo 3 Mo 4 Mo 5 Mo 6 Mo 7 Mo 8 Mo 9
TAC 11.7  3.2 6.0  3.6 3.2  2.2 3.0  3.2 2.0  1.8 1.5  1.5 1.5  1.6 1.6  1.7 1.7  2.0 1.4  1.7
CYC 11.9  1.5 10.4  1.9* 7.5  2.2* 4.9  2.4* 3.9  2.4* 3.4  1.9* 2.7  1.8 2.3  1.6 2.1  1.9 2.1  2.0
MMF 12.1  3.7 9.9  3.1* 8.1  3.0* 7.1  3.7* 5.9  3.8* 4.0  3.1* 3.1  3.0* 2.5  2.4 2.3  2.0 2.2  1.8
*p < 0.05, vs. TAC group at the same time point.
CYC Z cyclophosphamide; MMF Z mycophenolate mofetil; TAC Z tacrolimus.
16 L. Peng et al.fewer adverse effects than cyclosporine A in renal trans-
plantation.27 In recent years, TAC combined with low-dose
corticosteroids has become the first-line protocol in the
treatment of IMN because of its higher remission rate.15e18
The remission rate of TAC combined with corticosteroid in
our study was 90.0% at 6 months, which was close to the
rate found in other studies using the same regimen with
similar dosages.15e18,28 In our study, although the remission
rate of the TAC regimen at 6 months was slightly higher
than that of the CYC and MMF regimens, there was no
statistical difference in the remission rates between the
three groups. However, the TR rates in the TAC group at 1and 2 months were significantly higher than those in the
CYC and MMF groups. The same tendency existed in the
changes in urine protein and serum albumin. In summary,
compared with CYC and MMF therapy, TAC induced remis-
sion more quickly in patients at high risk for IMN and
significantly reduced the duration of treatment.
CR leads to an excellent long-term prognosis,29 and
achieving PR independently decreases the risk of renal
failure.30 Proteinuria is a risk factor for poor renal function
in kidney transplantation31 and in patients without diabetes
undergoing peritoneal dialysis.32 Furthermore, in patients
with IMN, the achievement of CR or PR significantly reduces
Table 5 The adverse events in the tacrolimus, cyclo-
phosphamide, and mycophenolate mofetil groups.
TAC
(N Z 30)
CYC
(N Z 30)
MMF
(N Z 30)
Infection 6 7 8
Respiratory
system infection
4 4 4
Urinary tract
infection
2 3 4
Diarrhea 1 1 3
Gastrointestinal reaction 0 4 1
Gastrointestinal bleeding 1 0 0
Hepatic lesion 2 3 2
Leukopenia 0 1 0
New-onset diabetes
mellitus
1 0 0
Hand tremor 6 0 0
Alopecia 0 2 0
Death 1 0 1
CYC Z cyclophosphamide; MMF Z mycophenolate mofetil;
TAC Z tacrolimus.
Comparison of different therapies in MN 17the risk for worsening renal function.14 In this study, the
early initiation of TAC treatment, resulting in the early
achievement of remission, may have contributed to the
renal function preservation in these patients. This conclu-
sion is consistent with previous study.18
The immunosuppressive effects of TAC could partially
explain its therapeutic effects in patients with IMN. How-
ever, calcineurin inhibitors can also reduce proteinuria in
Alport syndrome, which is a nonimmunological disease.33
TAC could have other therapeutic targets for its anti-
proteinuria activity in IMN independent of its immunolog-
ical effects. The actin cytoskeleton of podocytes is a direct
target of the antiproteinuric effect of the calcineurin in-
hibitor CsA.19 In addition, our recent study confirmed that
TAC can reduce angiopoietin-like-4 in podocytes to promote
podocyte repair in an animal model of IMN in the early
stage.20 This could be the mechanism by which TAC induced
remission earlier than other immunosuppressants.
TAC can produce adverse effects such as diabetes mel-
litus, hypertension, hand tremor, and nephrotoxicity.34 We
found only one patient with new-onset diabetes mellitus
and no patients with new-onset hypertension taking oral
TAC during the 9 months of observation. Decreased immune
function and body function, caused by aging, in one patient
undergoing TAC treatment led to severe respiratory system
infection and gastrointestinal bleeding, finally resulting in
death. Although this was an isolated incident, it demon-
strates the need to be more careful in treating elderly
patients. The nephrotoxicity of TAC has received much
attention from investigators. In this study, the dosage of
TAC was 0.05 mg/kg/d, and the trough concentration of
TAC was 4e8 ng/mL, which was lower than that reported in
kidney transplant recipients and patients with primary
nephrotic syndrome.35,36 Additionally, the dose of cortico-
steroid used in the TAC group was lower than that in the
other two groups in this study. Calcineurin inhibitor-related
nephrotoxicity is dose and time dependent.37e39 The reasonwhy TAC nephrotoxicity did not emerge in this study could
be the dose and duration of treatment. We did not find any
other severe side effects resulting from oral TAC adminis-
tration. These results demonstrate that the short-term use
of TAC was relatively safe.
This study has several limitations. First, the short follow-
up period prevents the generalization of our results. The
patients came from a single center, which limited the
number of samples. Because of a limited duration of follow
up, we cannot confirm the long-term effects or the lack of
other adverse events during long-term use of TAC, CYC, or
MMF. Second, the short observation time before immuno-
suppressant treatment is another limitation. We cannot
rule out the possibility of spontaneous remission, although
this rarely occurs in patients with severe proteinuria.
However, because the baseline characteristics were similar
between the three groups in our study, the probability of
spontaneous remission is also similar. Therefore, this should
have little influence on remission rate in three groups.
Third, the patients were all at pathological stage I to III. We
did not compare the remission rates between the different
stages because of the limited number of patients, so we
could not demonstrate the effects of the treatment regi-
ments at different pathological stages.
In conclusion, TAC, CYC, or MMF combined with corti-
costeroid is effective in the highest-risk patients with IMN.
TAC combined with corticosteroid had tolerable adverse
effects and was more rapid and more effective in inducing
the remission of IMN in the short term. The long-term ef-
fects require further investigation.
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